Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mastocytosis, Systemic 2Mastocytosis 2Gastrointestinal Stromal Tumors 2Blushing 2Recurrence 1Multiple Myeloma 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-Intestinal Stromal Tumour 1Colorectal Neoplasms 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × masitinib × Clear all
NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

AB Science

Phase 3 Terminated
147 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡